• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol . Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vacc

tetano

Editor, Senior Moderator
J Immunol


. 2025 Jan 1;214(1):104-114.
doi: 10.1093/jimmun/vkae013. Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered

Phillip Grovenstein[SUP] 1 [/SUP], Noopur Bhatnagar[SUP] 1 [/SUP], Ki-Hye Kim[SUP] 1 [/SUP], Surya Sekhar Pal[SUP] 1 [/SUP], Chau Thuy Tien Le[SUP] 1 [/SUP], Jannatul Ruhan Raha[SUP] 1 [/SUP], Rong Liu[SUP] 1 [/SUP], Chong Hyun Shin[SUP] 1 [/SUP], Bo Ryoung Park[SUP] 1 [/SUP], Lanying Du[SUP] 1 [/SUP], Jeeva Subbiah[SUP] 1 [/SUP], Bao-Zhong Wang[SUP] 1 [/SUP], Sang-Moo Kang[SUP] 1 [/SUP]



Affiliations
Abstract

Current influenza vaccines are not effective in conferring protection against antigenic variants and pandemics. To improve cross-protection of influenza vaccination, we developed a 5xM2e messenger RNA (mRNA) vaccine encoding the tandem repeat conserved ectodomain (M2e) of ion channel protein M2 derived from human, swine, and avian influenza A viruses. The lipid nanoparticle (LNP)-encapsulated 5xM2e mRNA vaccine was immunogenic, eliciting high levels of M2e-specific IgG antibodies, IFN-γ+ T cells, T follicular helper cells, germinal center phenotypic B cells, and plasma cells. The mice with 5xM2e mRNA vaccination were broadly protected against lethal infection regardless of hemagglutinin (H1, H3, H5) subtypes by preventing severe weight loss. Injection of 5xM2e mRNA LNP vaccine induced acute innate responses recruiting monocytes, macrophages, and diverse subsets of dendritic cells. A single dose of combined 5xM2e mRNA LNP and split vaccines resulted in significantly enhanced and sustainable IgG antibody responses to viral antigens and protection against homologous and heterologous viruses. This study provides a new strategy of combined mRNA and seasonal vaccination, significantly enhancing vaccine protective efficacy.

Keywords: influenza; mRNA vaccine; mice; viral.

 
Back
Top Bottom